Skip to main content

Peer Review reports

From: Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

Original Submission
27 Sep 2019 Submitted Original manuscript
14 Dec 2019 Reviewed Reviewer Report - Sachio Fushida
28 May 2020 Author responded Author comments - Kenro Hirata
3 Jun 2020 Author responded Author comments - Kenro Hirata
Resubmission - Version 2
28 May 2020 Submitted Manuscript version 2
6 Jun 2020 Editorially accepted
12 Jun 2020 Article published 10.1186/s12885-020-07047-1

You can find further information about peer review here.

Back to article page